Gilead Sciences, Inc. revenue breakdown overview

Gilead Sciences, Inc. revenue for the last year amounted to 28.75 B USD, the most of which — 19.61 B USD — came from its highest performing source at the moment, Human Immunodeficiency Virus, the year earlier bringing 18.18 B USD. The greatest contribution to the revenue figure was made by United States — last year it brought Gilead Sciences, Inc. 20.59 B USD, and the year before that — 19.44 B USD.